

1 **Strain Construction**

2 *C. albicans* strain CaLC5543 was constructed using the CRISPR Cas9 system previously
3 described.⁵⁶ *C. auris* strains were constructed using homologous recombination and an
4 electroporation transformation approach as described previously.⁵⁷

5
6 **CaLC5543: *C. albicans* Tif1^{L153F}/Tif1^{L153F}**

7 To alter residue 153 from a leucine to a phenylalanine in *C. albicans*, repair primers oLC6944 and
8 oLC6945 containing the nucleotide change from A to C were annealed. pLC1089 was digested
9 with KpnI and SacI and transformed into CaLC239 (SN95) along with the repair piece. Colonies
10 were patched and PCR using oLC6972 and oCL6923 was employed to amplify 400 bp to send for
11 sequencing to confirm base change.

12
13 **CauLC5813: *C. auris* eIF4A-NAT**

14 The eIF4A-NAT construct was amplified from pLC1105 with oLC7157 and oLC7158. The
15 construct was ethanol precipitated and transformed into *C. auris* CauLC5083 using a standard
16 electroporation protocol and plated on YPD-NAT plates. Integration was verified using primer
17 pairs oLC7153/6398 and oLC274/7156.

18
19 **CaLC5814: *C. auris* eIF4A^{F152L} NAT**

20 The eIF4A-NAT construct was amplified from pLC1106 with oLC7157 and 7158. The construct
21 was ethanol precipitated and transformed into *C. auris* CauLC5083 using a standard
22 electroporation protocol and plated on YPD-NAT plates. Integration was verified using primer
23 pairs oLC7153/6398 and oLC274/7156.

24 **CaLC6610: *C. auris mca1Δ*:: NAT**

25 To delete *MCA1*, ~1kb upstream and downstream of the gene was amplified using primers
26 oLC7720/oLC7721 and oLC7722/oLC7723 and the NAT marker from pLC1049 was amplified
27 using oLC6296/oLC6304. Fusion PCR using nested primers oLC7724/oLC7725 was used to
28 create the final construct. Integration was verified using primers oLC7720/oLC6308 and
29 oLC274/oLC7723 and absence of wild type band (oLC7727/oLC7728).

30

31 **pLC1089:** To alter residue 153 from a leucine to a phenylalanine in *C. albicans*, pLC963 was
32 digested with BsmBI and ligated with annealed sgRNAs oLC6918 and oLC6919 directed towards
33 *TIF1*. This was transformed into DH5 α making pLC1089. Colonies were sequenced to verify
34 guide using oLC4609.

35

36 **pLC1105:** ~1kb homology to the *C. auris* eIF4A locus was amplified: upstream (oLC7153/7154)
37 and downstream (oLC7155/7156) with 40bp overlap to NAT marker. The NAT marker from
38 pLC1049 was amplified using oLC6296/oLC6304. Fusion PCR with nested primers
39 (oLC7157/7158) containing cut sites XmaI for upstream and SacI for downstream produced a full
40 length 3.5kb construct. pUC19 and the construct were digested independently with XmaI and SacI
41 overnight and ligated at a ratio of 3:1 intert:vector. 5uL of mixture was transformed into DH5alpha
42 and plated on LB plates with 100 μ g/mL ampicillin. Colonies were verified for integration
43 upstream with oLC243/7166 and downstream with oLC244/7167. Correctly genotyped colonies
44 were sequence verified with tiling primers oLC7200-7204 and oLC3854.

45

46 **pLC1106**: From pLC1105, site-directed mutagenesis was performed using oLC7161/7162 as
47 previously described. Dpn1 was used to remove remaining template DNA and 10 ng was
48 transformed into Max Efficiency DH5 α . Sanger sequencing was used to confirm the mutation with
49 oLC7163 and then tiling primers were used to confirm no other mutations had occurred (oLC7200-
50 7204 and oLC3854).

51

52 **Fluorescent Translation Assay**

53 Briefly, cells were grown in minimal YNB medium until log phase (\sim OD₆₀₀ 0.4) was reached.
54 Cells were then treated for 10 minutes with either 10 μ g/mL of the known translation inhibitor
55 cycloheximide (AG Scientific Inc.) or 50 μ M of each rocaglate identified from the screen as
56 indicated. The HPG alkyne methionine analog was added to the cells for 30 minutes and then cells
57 were fixed using v/v 70% ethanol for 1 hour rocking. Cells were pelleted by centrifugation and
58 washed twice with 3% BSA in PBS. The reaction cocktail containing the azide fluorophore was
59 used to resuspend pelleted cells at a volume based on the volume of the initial sample. Samples
60 were incubated for 30 minutes in the dark at room temperature. Cells were then washed with the
61 rinse buffer and resuspended in PBS. Cells were imaged by differential interference contrast
62 microscopy and the EGFP channel on a Zeiss Axio Imager.MI (Carl Zeiss) at the same exposure
63 time.

64

65 **BCECF-AM Staining and Quantification**

66 Briefly, strains were sub-cultured at OD₆₀₀ of 0.2 from a saturated overnight culture at 30°C with
67 agitation for 2.5 hours in YPD medium buffered to pH 5.5 in 2-(N-morpholino)ethanesulfonic acid
68 (MES; Bioshop). Cells were then treated with 50 μ M CMD010515 for 60 minutes at 30 °C with

69 agitation. The cultures were then further incubated under the same conditions with 25 $\mu\text{g}/\text{mL}$
70 BCECF-AM for 30 minutes. Cells were washed 2X in PBS and resuspended in PBS. Cells were
71 either imaged by differential interference contrast microscopy and the EGFP channel on a Zeiss
72 Axio Imager.MI (Carl Zeiss) with the exposure time remaining constant between samples of the
73 same species, or brightness was quantified on a CytoFlex Flow Cytometer (Beckman).

74

75 **Mitochondrial Membrane Potential Assay**

76 Cells were sub-cultured at OD_{600} of 0.2 from a saturated overnight culture at 30°C with agitation
77 for 2 hours in YPD medium. For TMRE treatment, TMRE was added to cultures at a concentration
78 of 100 nM and cells were incubated for 30 minutes. Cells were then treated with 50 μM
79 CMD010515 for 4 hours at 30°C with agitation. For MitoTracker Red, after the initial sub-culture
80 cells were treated with 50 μM CMD010515 for 3 hours at 30°C with agitation. MitoTracker Red
81 was added to the culture at 50 nM and the cells were further incubated for 40 minutes. For both
82 treatments cells were washed and resuspended in PBS. Cells were imaged by differential
83 interference contrast microscopy and the DsRed (MitoTracker Red) or TexasRed (TMRE) channel
84 on a Zeiss Axio Imager.MI with the exposure time remaining constant between samples. For the
85 MitoTracker Red treated cells, brightness was also quantified on a CytoFlex Flow Cytometer
86 (Beckman).

87

88 **TUNEL Assay**

89 Yeast cells were sub-cultured at OD_{600} of 0.2 from a saturated overnight culture at 30°C with
90 agitation for 2 hours in YPD medium. Cells were then treated with 50 μM CMD010515 for 4 and
91 6 hours at 30°C with agitation. At each time point cells were pelleted and fixed with 3.7% (vol/vol)

92 formaldehyde for 1 hour at room temperature and then washed three times with PBS. The cell wall
93 was digested with 24 µg/mL Zymolyase 100T (10⁵ units/g; MP Biomedicals, Irvine, CA) at 37°C
94 for 60 minutes. For microscope visualization, 10 µL of the cell suspension was applied to a
95 microscope slide and allowed to dry for 30 minutes at 37°C. The remaining treated cells were kept
96 within an eppendorf tube. Cells were rinsed with PBS and then incubated in permeabilization
97 solution: [0.1% (vol/vol) Triton X-100 and 0.1% (wt/wt) sodium citrate] for 2 minutes on ice. Cells
98 were rinsed twice with PBS. The positive control of 30 U DNaseI was added to the cells on
99 microscope slides. The slides were placed in a humidified box for 1 hour at 37°C. They were then
100 washed for 15 minutes twice in PBS. Slides were incubated with 10 µL of TUNEL reaction mixture
101 (terminal deoxynucleotidyl transferase and fluorescein isothiocyanate dUTP) for 60 minutes at
102 37°C. Cells were rinsed three times with PBS and 5 µL of 50% glycerol was added to cells on the
103 slide.

104

105 **Caspase-like Activity Assay**

106 Cells were sub-cultured to an OD₆₀₀ of 0.1 and grown for 18 hours in the absence or presence of
107 50 µM rocaglate CMD010515. Cells were pelleted and resuspended in buffer containing the
108 fluorescent caspase substrate. Cells were incubated for 45 minutes, washed, and resuspended in
109 PBS. Propidium iodide was added at 1 µg/mL to visualize dead cells.

110

111 **Transmission Electron Microscopy**

112 Cells were fixed prior to rocaglate treatment and after 30 minutes or 2 hours of treatment by
113 combining cell culture 1:1 with 2X of a prefixative solution (0.2 M PIPES pH 6.8, 0.2 M sorbitol,
114 2 mM MgCl₂, 2 mM CaCl₂, 4% glutaraldehyde in ddH₂O). Cells were incubated in fixative for 5

115 minutes, spun down at 1500g for 5 minutes and then resuspended in 1X prefixative solution. Cells
116 were incubated overnight at 4°C. Cells were then washed 3X in ddH₂O and resuspended in in 5
117 mL of 2% aqueous solution of potassium permanganate for 5 minutes. Cells were pelleted and
118 resuspended in fresh 2% potassium permanganate and incubated for 45 minutes. Cells were
119 washed with ddH₂O and the En-Bock stain was added by overlaying the cell pellet with 1% uranyl
120 acetate and incubating at room temperature for 1 hour followed by washing 3X with ddH₂O. Celled
121 were dehydrated by pelleting and washing 2X in 30% ethanol for 30 minutes each. This was
122 repeated with 50, 70, and 90% ethanol and finally 3X with 100% ethanol for two hours each. One
123 part Spurr's resin mixed with two parts 100% ethanol was added to the cells for 3 hours using an
124 agitator, followed by two parts Spurr's resin mixed with one part 100% ethanol for 4 hours. 100%
125 Spurr's resin was added overnight using an agitator and finally one more change with fresh Spurr's
126 with agitation for 2 hours.

127

128 **FM4-64 Staining and Quantification**

129 Rocaglate-sensitive *C. auris* (CaLC5083) and *C. albicans* (CaLC5543) were sub-cultured to an
130 OD₆₀₀ of 0.2 from a saturated overnight culture in YPD medium at 30°C with agitation for 2.5
131 hours. FM4-64 (ThermoFisher) was added to the cultures to a concentration of 5 μM and shaking
132 incubation was continued for 30 minutes. Cells were washed with YPD, resuspended back to the
133 original volume in YPD, and treated with 50 μM CMLD010515 for a 90 minute outgrowth at 30
134 °C with agitation. Cells were washed 2X in PBS and resuspended in PBS.

135

136

137

138

139

140

141 **Supplementary References**

- 142 1. **Chatterjee S, Alampalli SV, Nageshan RK, Chettiar ST, Joshi S, Tatu US.** 2015.
143 Draft genome of a commonly misdiagnosed multidrug resistant pathogen *Candida auris*.
144 BMC Genomics **16**:686.
- 145 2. **Butler G, Rasmussen MD, Lin MF, Santos MAS, Sakthikumar S, Munro CA,**
146 **Rheinbay E, Grabherr M, Forche A, Reedy JL, Agrafioti I, Arnaud MB, Bates S,**
147 **Brown AJP, Brunke S, Costanzo MC, Fitzpatrick DA, de Groot PWJ, Harris D,**
148 **Hoyer LL, Hube B, Klis FM, Kodira C, Lennard N, Logue ME, Martin R, Neiman**
149 **AM, Nikolaou E, Quail MA, Quinn J, Santos MC, Schmitzberger FF, Sherlock G,**
150 **Shah P, Silverstein KAT, Skrzypek MS, Soll D, Staggs R, Stansfield I, Stumpf MPH,**
151 **Sudbery PE, Srikantha T, Zeng Q, Berman J, Berriman M, Heitman J, Gow NAR,**
152 **Lorenz MC, Birren BW, Kellis M, Cuomo CA.** 2009. Evolution of pathogenicity and
153 sexual reproduction in eight *Candida* genomes. Nature **459**:657–62.
- 154 3. **Noble SM, Johnson AD.** 2005. Strains and strategies for large-scale gene deletion studies
155 of the diploid human fungal pathogen *Candida albicans*. Eukaryot. Cell **4**:298–309.
- 156 4. **Staib P, Morschhäuser J.** 1999. Chlamydospore formation on staib agar as a species-
157 specific characteristic of *Candida dubliniensis*. Mycoses **42**:521–524.
- 158 5. **Cormack BP, Falkow S.** 1999. Efficient homologous and illegitimate recombination in
159 the opportunistic yeast pathogen *Candida glabrata*. Genetics **151**:979–87.
- 160 6. **Giaever G, Chu AM, Ni L, Connelly C, Riles L, Véronneau S, Dow S, Lucau-Danila**
161 **A, Anderson K, André B, Arkin AP, Astromoff A, El Bakkoury M, Bangham R,**
162 **Benito R, Brachat S, Campanaro S, Curtiss M, Davis K, Deutschbauer A, Entian K-**

163 **D, Flaherty P, Foury F, Garfinkel DJ, Gerstein M, Gotte D, Güldener U, Hegemann**
164 **JH, Hempel S, Herman Z, Jaramillo DF, Kelly DE, Kelly SL, Kötter P, LaBonte D,**
165 **Lamb DC, Lan N, Liang H, Liao H, Liu L, Luo C, Lussier M, Mao R, Menard P, Ooi**
166 **SL, Revuelta JL, Roberts CJ, Rose M, Ross-Macdonald P, Scherens B, Schimmack**
167 **G, Shafer B, Shoemaker DD, Sookhai-Mahadeo S, Storms RK, Strathern JN, Valle**
168 **G, Voet M, Volckaert G, Wang C, Ward TR, Wilhelmy J, Winzeler EA, Yang Y, Yen**
169 **G, Youngman E, Yu K, Bussey H, Boeke JD, Snyder M, Philippsen P, Davis RW,**
170 **Johnston M.** 2002. Functional profiling of the *Saccharomyces cerevisiae* genome. *Nature*
171 **418:387–391.**

172 7. **Granger DL, Perfect JR, Durack DT.** 1985. Virulence of *Cryptococcus neoformans*.
173 Regulation of capsule synthesis by carbon dioxide. *J. Clin. Invest.* **76:508–16.**

174 8. **Kim SH, Iyer KR, Pardeshi L, Muñoz JF, Robbins N, Cuomo CA, Wong KH, Cowen**
175 **LE.** 2019. Genetic analysis of *Candida auris* implicates Hsp90 in morphogenesis and
176 azole tolerance and Cdr1 in azole resistance. *MBio* **10:e02529-18.**

177 9. **Geng J, Nair U, Yasumura-Yorimitsu K, Klionsky DJ.** 2010. Post-Golgi Sec proteins
178 are required for autophagy in *Saccharomyces cerevisiae*. *Mol. Biol. Cell* **21:2257–69.**

179 10. **Piotrowski JS, Li SC, Deshpande R, Simpkins SW, Nelson J, Yashiroda Y, Barber**
180 **JM, Safizadeh H, Wilson E, Okada H, Gebre AA, Kubo K, Torres NP, LeBlanc MA,**
181 **Andrusiak K, Okamoto R, Yoshimura M, DeRango-Adem E, van Leeuwen J,**
182 **Shirahige K, Baryshnikova A, Brown GW, Hirano H, Costanzo M, Andrews B, Ohya**
183 **Y, Osada H, Yoshida M, Myers CL, Boone C.** 2017. Functional annotation of chemical
184 libraries across diverse biological processes. *Nat. Chem. Biol.* **13:982–993.**

185 11. **Veri AO, Miao Z, Shapiro RS, Tebbji F, O’Meara TR, Kim SH, Colazo J, Tan K,**

186 **Vyas VK, Whiteway M, Robbins N, Wong KH, Cowen LE.** 2018. Tuning Hsf1 levels
187 drives distinct fungal morphogenetic programs with depletion impairing Hsp90 function
188 and overexpression expanding the target space. *PLoS Genet.* **14**:e1007270.

189 12. **Norrande J, Kempe T, Messing J.** 1983. Construction of improved M13 vectors using
190 oligodeoxynucleotide-directed mutagenesis. *Gene* **26**:101–106.

191